A question of standards  by Purvis, Gail
III-Vs REVIEW THE ADVANCED SEMICONDUCTOR MAGAZINE VOL 17 - NO 7 - SEPTEMBER/OCTOBER 20042
For those in the III-Vs semiconductor
industry who feel that ‘nano’ might have
research funding value, despite already
being fait accomplis in compound devices,
the American National Standards Institute
has formed a Nanotechnology Standards
Panel (ANSI-NSP), a new coordinating
body for development of standards in 
nanotechnology. 
The panel met 29-30 September, at NIST,
Gaithersburg, MD, focusing on nomen-
clature & terminology. ANSI-NSP is open
to all interested parties and issued a call
to organisations and individuals working
or familiar with nanotechnology, to consid-
er participating on the panel and steering
committee. (Information is available on
the ANSI website:www. ansi. org/nsp. )
In a quite different question of standards,
namely the impartiality of health research,
a row has emerged over a UK cancer study
being conducted among  chip manufactur-
ing workers of a semiconductor plant.
This is at a time when the US Semicon-
ductor Industry Association (SIA) is about
to award its own large scale US study into
the  industry’s health.
In the UK, a group of workers are pointing
out that the Scottish-based Institute of
Occupational Medicine, contracted by the
UK government to conduct its study, has
now admitted that at least one employee
has done consulting work for National
Semiconductor, in California. 
The argument is that the group's ties to
the semiconductor industry make it
unable to conduct unbiased research.
The UK government launched its follow-up
study after a smaller work found that for-
mer workers at National Semiconductor in
UK had a higher-than-average rate of cer-
tain cancers — specifically, lung, gastric,
and breast cancers in women, and brain
tumours in men. IOM was awarded the
contract to conduct that follow-up study
almost two years ago. It denied then hav-
ing any links to the semiconductor indus-
try, only recently admitting to this.
The issue is again highlighted  in a recent
medical journal’s controversial refusal to
publish a paper including mortality data of
former workers in semiconductor plants at
IBM. These showed  higher-than-average
rate of certain cancers. 
While IBM and others currently conduct
their own studies into work related health
effects, there are serious doubts about
impartiality. Even an industry doyen like
the Mayo Clinic, has its semiconductor
research interests.
The SIA however says that research into
the health effects of the industry cannot
be totally independent, because investiga-
tors will have to work with companies who
provide the company data. And, argues
the SIA, companies do not want to cover
up the truth. 
Let’s hope the winning research body for
SIA’s magnus opus is well above reproach.
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